In addition to semaglutide, albiglutide, exenatide, liraglutide, lixisenatide, and dulaglutide are all GLP-1 receptor agonists available in the market with no reports of hyposalivation or even xerostomia as an expected adverse effect have been published.[17] It could be reasonable to start educating patients about to start on semaglutide on the risk of hyposalivation and the need for close follow up with their dentists for early detection and management. The gene discussed is GLP1R; the disease is xerostomia.